BioStem Technologies (OTC: BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. Both the diabetes wound care market and surgical recovery wound care market are growing at a tremendous rate and offer BSEM a big opportunity, especially because diabetes and issues from diabetes are increasing worldwide.
A recent study confirmed that BSEM technology is superior and very helpful to patients. More doctors are turning to BioStem for treatments, resulting in increasing sales helping the company score record revenues in 2024!
BioStem Technologies Inc. (OTC: BSEM) has just achieved another major milestone with its third consecutive quarter of record growth! In Q3 2024, the company posted revenue of $82.6 million for the quarter, totaling $199 million for the first nine-months of 2024.
This strong financial performance is a direct result of the continued success of BSEM’s AmnioWrap2® allografts using the company’s patented BioREtain® technology, which is driving increased commercial acceptance across a wide range of non-acute sites of service.
Following BSEM’s Q3 results, Zack’s Small Cap Research increased its price target from $24.25 to $32.50!
